andecaliximab   Click here for help

GtoPdb Ligand ID: 9510

Synonyms: GS-5745 | GS5745
Immunopharmacology Ligand
Compound class: Antibody
Comment: Gilead Sciences designed andecaliximab (GS-5745), a humanized anti-MMP9 monoclonal antibody, for potential to treat solid tumours and inflammatory disorders [1-2]. GS-5745 inhibits MMP-9 activity by a combination of blocking proenzyme (zymogen) conversion to active enzyme, and allosterically inhibiting active MMP-9 catalytic activity [1].
Click here for help
Immunopharmacology Comments
Having initiated Phase 2 clinical trials in ulcerative colitis, Crohn's disease and rheumatoid arthritis, development of andecaliximab for inflammatory diseases appears to have been discontinued and all clinical trials terminated.
Immunopharmacology Disease
Disease X-Refs Comment References
Chronic obstructive pulmonary disease Disease Ontology: DOID:3083
Phase 1 study in COPD (NCT02077465) has been completed.
Rheumatoid arthritis Disease Ontology: DOID:7148
OMIM: 180300
Phase 2 clinical trial in RA patients has been terminated (see NCT02862574).